Gecacitinib hydrochloride (JAK/ACVR1 inhibitor)

Current understanding

To be populated as evidence accumulates.

2026-03-13 — Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis: Prospective trial extends gecacitinib use to the full peri-transplant window (pre-, during-, and post-HSCT) in primary or secondary myelofibrosis, evaluating efficacy and safety as a comprehensive transplant-bridging protocol (trial-early). (novelty: 3)
2026-03-30 — Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation: cross-connection with itacitinib-tacrolimus-sirolimus-gvhd: Both are novel selective JAK inhibitors being tested for aGVHD prophylaxis in MF/leukemia patients undergoing allo-HSCT, representing parallel efforts to refine the ruxolitinib-pioneered JAK-inhibition-for-GVHD paradigm. (novelty: 3)
2026-02-27 — Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis: Early-phase trial evaluating gecacitinib hydrochloride combined with ATG for acute GVHD prophylaxis in myelofibrosis patients undergoing allogeneic HSCT — first-in-class application of JAK/ACVR1 dual inhibition in the transplant setting (trial-early). (novelty: 4)